Infectious Disease Models for Vaccine Safety and Efficacy Studies
When Alexander Fleming inadvertently discovered penicillin in 1928, the world assumed that the age-old scourge of infectious diseases was about to end. For decades, newly synthesized antibiotics arrested killers such as tuberculosis and syphilis, while cutting-edge antivirals saved millions of people from polio and smallpox.
Sadly, infectious diseases remain a deadly force worldwide. Bacteria develop resistance to antibiotics, often faster than new drugs can be created. New viruses continue to emerge, from HIV to SARS to endless mutations of influenza. In undeveloped countries, people still face deadly threats such as malaria and measles.
Charles River joins forces with pharmaceutical and biotechnology sponsors in the race to develop new vaccines, antibacterials, and antivirals. Our technical capabilities, scientific accuracy, and depth of experience set the pace for research in infectious diseases.
Our Biosafety Level 2 (BSL2) barrier facilities (PDF available through The Source℠) can deliver results under high regulatory standards and at a competitive price. We can conduct vaccine safety (and efficacy) studies in the following species as well as challenge work under BSL2 conditions:
- Guinea pig
- Large animals
We also offer infectious disease pharmacology models for discovery.
Endpoints and Capabilities
- BSL2 laboratory and vivarium space
- Bacterial enumeration in tissues and organs
- Inoculation routes, including but not limited to intratracheal, nasal, intravaginal, and intramuscular options
- BSL2 challenge studies (with a few exceptions based on review of the challenge material)
- Frozen bacterial stocks and ATCC availability
- Antigen-specific responses (titering and isotyping)
- T helper cell (Th1/Th2) ex vivo analysis